Prometic enters into binding agreement to secure $25 million follow-on financing from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc. Français
- Total investment in Prometic from Peter J. Thomson's Toronto-based investment vehicle amounting to $85 million
- $25 Million debt financing to bear interest of 8.5% per annum and repayable in July, 2022
- No material additional security to be granted by Prometic over and beyond the existing debt package
- 10,600,407 warrants to be granted at an exercise price of $3.70, a premium of 70% to the most recent Prometic share price close
- Aggregate proceeds from exercise of warrants to offset the total amount repayable under the debt instrument
LAVAL, QC, March 24, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has entered into a binding agreement to secure a follow-on investment from Structured Alpha LP, an affiliate of Peter J. Thomson's investment firm, Thomvest Asset Management Inc., consisting of a $25 million loan (the "Loan"). As partial consideration for the Loan, Prometic will grant Structured Alpha LP 10,600,407 warrants with an exercise price of $3.70 per common share, a premium of 70% to yesterday's closing share price, the whole subject to obtaining TSX approval and closing the definitive documentation, which the parties expect to achieve over the next 30 days.
"Prometic is now only a few months away from officially becoming a fully integrated biopharmaceutical company with its first commercially approved drug, plasminogen, expected to be launched in Q4 this year", stated Mr. Pierre Laurin, President and Chief Executive Officer of Prometic Life Sciences Inc. "It is key for us to remain sufficiently capitalized to execute on our corporate initiatives and clinical programs as we continue delivering on the expected catalysts events. We intend to fully leverage this follow-on investment to generate value for all our shareholders", added Mr. Laurin.
Commenting on the additional follow-on investment in Prometic, Stefan Clulow, Managing Director and Chief Investment Officer of Thomvest Asset Management Inc., said: "We see 2017 as a transformational year for Prometic. The commercialization of the company's first plasma-derived therapeutic will validate its proprietary PPPS platform and should focus the market's attention on the therapeutic pipeline it enables. Prometic is demonstrating how good strategy, innovation and execution can be combined to bring cost-effective novel therapies to patients while creating value for all stakeholders. We are proud to support Mr. Laurin and the rest of the Prometic team in their efforts."
The Loan shall be secured by Prometic's assets, excluding its patent portfolio. The redemption value of the Loan implies a compounded annual interest rate of 8.5%. No interest or principal shall be required to be repaid prior to July 31, 2022. As part of this transaction, Prometic shall grant Structured Alpha LP a warrant to purchase 10,600,407 common shares at an exercise price of $3.70 per common share with a term expiring in October, 2023. The proceeds received by Prometic from the aggregate exercise of all of the warrants would be sufficient to repay the Loan in its entirety. No material additional security or covenants have been granted to Structured Alpha LP, over those already in place by the current original issue discount notes.
About Thomvest Asset Management Inc. And Structured Alpha LP
Thomvest Asset Management Inc. is a Toronto-based investment management firm controlled by Peter J. Thomson. Structured Alpha LP is an affiliate of Thomvest Asset Management Inc. that makes structured investments in companies that leverage disruptive technologies and business models to pursue high-growth commercial opportunities. We are committed to the success of our entrepreneur partners. The capital we invest is our own, enabling us to be more creative, flexible, strategic and patient than most investors. It takes time to build great companies and Thomvest and its affiliates are committed to supporting its entrepreneurs throughout their journey. To learn more about Thomvest, please visit us at www.thomvest.com.
About Prometic Life Sciences Inc.
Prometic Life Sciences Inc. (www.prometic.com) is a long established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. Prometic is active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, cancer and autoimmune diseases/inflammation. A number of plasma-derived and small molecule products are under development for orphan drug indications. Prometic also offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. Headquartered in Laval (Canada), Prometic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S., Canada, Europe, Russia, Australia and Asia.
Forward Looking Statements
This press release contains forward-looking statements about Prometic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Prometic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Prometic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Prometic's Annual Information Form for the year ended December 31, 2016, under the heading "Risk and Uncertainties related to Prometic's business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.
SOURCE ProMetic Life Sciences Inc.
Pierre Laurin, President and CEO, Prometic Life Sciences Inc., [email protected], 450.781.0115; Frederic Dumais, Senior Director, Communications & Investor Relations, Prometic Life Sciences Inc., [email protected], 450-781-0115
Share this article